Left behind? Drug discovery in extensive-stage small-cell lung cancer

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.

Original languageEnglish (US)
Pages (from-to)93-95
Number of pages3
JournalClinical Lung Cancer
Issue number2
StatePublished - Mar 2014


  • Amrubicin
  • Chemotherapy
  • Clinical trials
  • Developmental therapeutics
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Left behind? Drug discovery in extensive-stage small-cell lung cancer'. Together they form a unique fingerprint.

Cite this